Arcus Biosciences insider plans sale of 14,000 shares of stock

Rhea-AI Filing Summary

A Rule 144 notice for Arcus Biosciences (RCUS) indicates that stockholder Robert C. Goeltz II plans to sell 14,000 shares of common stock through E*TRADE Financial on the NYSE, with an aggregate market value of 306,600 and an approximate sale date of 12/16/2025.

The shares to be sold come from restricted stock that vested on 12/15/2025 from grants originally awarded on 3/8/2022, 1/23/2023, 1/23/2024, and 1/23/2025 as consideration for services rendered. The notice also reports 122,856,086 shares outstanding and discloses additional recent sales by the same seller of 5,000 shares for gross proceeds of 125,000 on 11/26/2025 and 5,000 shares for 100,000 on 10/28/2025, providing context for his recent trading activity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock sale does the Arcus Biosciences (RCUS) notice describe?

The notice states that Robert C. Goeltz II plans to sell 14,000 shares of Arcus Biosciences common stock through E*TRADE Financial on the NYSE.

What is the aggregate market value of the Arcus Biosciences (RCUS) shares to be sold?

The 14,000 Arcus Biosciences shares listed for sale have an aggregate market value of 306,600 according to the notice.

When are the Arcus Biosciences (RCUS) shares expected to be sold and on which exchange?

The approximate sale date is listed as 12/16/2025, and the planned sales are on the NYSE.

How did the seller acquire the Arcus Biosciences (RCUS) shares mentioned in the notice?

The shares relate to restricted stock that vested on 12/15/2025 from grants dated 3/8/2022, 1/23/2023, 1/23/2024, and 1/23/2025, received as services rendered.

How many Arcus Biosciences (RCUS) shares are reported as outstanding in the notice?

The notice reports 122,856,086 shares of Arcus Biosciences common stock outstanding.

What other recent Arcus Biosciences (RCUS) stock sales by the same seller are disclosed?

The notice lists additional sales by Robert C. Goeltz II of 5,000 shares for gross proceeds of 125,000 on 11/26/2025 and 5,000 shares for 100,000 on 10/28/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/15/2025 - 06:21 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001653881
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcus Biosciences, Inc.
SEC File Number	001-38419
Address of Issuer	3928 Point Eden Way Hayward CALIFORNIA 94545
Phone	5106946200
Name of Person for Whose Account the Securities are To Be Sold	Robert C. Goeltz, II
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	E*TRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 3005	14000	306600	122856086	12/16/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	12/15/2025	Vesting of restricted stock granted 3/8/2022	Arcus Biosciences, Inc.			3875	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2023	Arcus Biosciences, Inc.			8500	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2024	Arcus Biosciences, Inc.			5500	12/15/2025	Services rendered
COMMON	12/15/2025	Vesting of restricted stock granted 1/23/2025	Arcus Biosciences, Inc.			9250	12/15/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Robert C. Goeltz II 3928 Point Eden Way Hayward CA 94545	Common Stock	11/26/2025	5000	125000
Robert C. Goeltz II 3928 Point Eden Way Hayward CA 94545	Common Stock	10/28/2025	5000	100000

144: Remarks and Signature

Remarks	The reported transactions represent mandatory sell-to-cover transactions effected pursuant to the Issuer's equity administration policy.
Date of Notice	12/15/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/22/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Carolyn Tang
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)